Dermatomyositis post vaccine against SARS-COV2

Adolfo Camargo Coronel, Francisco Javier Jiménez Balderas, Horacio Quiñones Moya*, Mario Raúl Hernández Zavala, Pedro Mandinabellita Rodríguez, José Ramiro Hernández Vázquez, Sandy Zamora Zarco and Sergio De Jesús Aguilar Castillo

Abstract

Background: Dermatomyositis belongs to an infrequent group of diseases predominantly found in patients older than 40 years old and is characterized by dermal and muscular findings. This disease presents itself as proximal, ascending and symmetric weakness and typical dermatosis with findings such as elevated muscle enzymes, altered electromyography and typical changes in muscle biopsy; as of today, the etiology of the disease is unknown. The COVID-19 vaccine has been a fundamental tactic to achieve control of the coronavirus (SARS CoV2), and it’s clear that the benefits of getting the vaccine overweight the risks that might come along with it. Although rare, all adverse effects should be reported, this could help us to understand the elusive pathophysiology of inflammatory idiopathic myopathy.

Case presentation: In this text we will describe the case of a patient with dermatomyositis who was vaccinated against SARS CoV2 with BNT162b2 mRNA (Pfizer-BioNTech), showing a temporal relation between the vaccination and the beginning of her symptoms. We realized all the diagnostic approach to the suspected disease including electromyography, muscle biopsy and laboratory findings, corroborating the diagnosis. The patient received standard treatment for this disease (steroid therapy) and have a classic slow improvement.

Conclusions: Although it’s not possible to confirm a direct correlation between the vaccine and the onset of the disease, we considered that there are enough data to suspect that this could be a trigger event and therefore should always be considered a possible cause for a case of inflammatory idiopathic myopathy.

Keywords: Dermatomyositis, COVID-19, Vaccine

Background

Idiopathic Inflammatory myopathies (IIM; also known collectively as myopathies) are a heterogeneous group of immunemediated pathologies that present chronic muscular inflammation that leads up to muscle weakness [1]. They are subdivided in 4 groups: dermatomyositis (DM), polymyositis (PM), necrotizing autoimmune myopathy (NAM) and inclusion bodies myopathy (IBM). These subtypes are based primarily on the most predominant affection on either the skin or muscle [1, 2].

The pathogenesis is complicated and currently is not fully known but it responds well to immunosuppressant therapy which means there is an autoimmune response at the core of the disease.

Vaccines are a major contribution to public health on modern age and act as a powerful stimulus to the immune system which, theoretically, has the potential to induce or exacerbate immune processes shown as serologic findings or clinical autoimmune diseases.
Even though a clear relation between the inflammatory myopathies and vaccination hasn't been found, there are many case reports of vaccine associated myopathies. Any described association between immunization and autoimmune reaction is mostly temporal, not causal. Several trials and studies trying to prove any causal association between the two has had negative results. These findings are backed up by the fact that there has been no increased incidence of autoimmune diseases in the period of time surrounding big vaccination campaigns [3].

This studies, however, lack the statistical power to rule out any “extremely rare” causal association suggested by the case reports. It’s not unreasonable to propose that vaccines could induce several immune reactions in genetically predisposed individuals that could add up to an autoimmune disease, still, there is no irrefutable evidence that shows a causal association between vaccination and autoimmunity. Up until August 23 of 2021, the VAERS (Vaccine Adverse Event Reporting System) had registered 77 cases of vaccine associated dermatomyositis, of which 17 of them (22.7%) were attributed to SARS-CoV2 vaccines (7 from Pfizer-BioNtech, 9 from Moderna and 1 from Jansen); 3 cases of inclusion bodies myopathy of which 2 (66.7%) were associated to SARS-CoV2 vaccines (1 from Moderna, 1 from Pfizer-BioNTech); 26 cases of polymyositis of which 6 (23.06%) were associated to SARS-CoV2 vaccines (4 from Moderna and 2 from Pfizer-BioNTech); and 4 cases of immune mediated myositis, all of which were associated to the SARS-CoV2 vaccine (3 from Moderna and 1 from Pfizer-BioNTech) [4]. It’s worth mentioning that these reports are limited to USA and that any report just clarifies however, that up to this point, more than 60% of north americans (approximately 192 million people) [12] has received at least one dose of the COVID19 vaccine and there has only been 32 myopathy cases reported in the VAERS (0.00016% of the vaccinated population), so, in case of proving causal relation the risk of presenting this complication would be very low and wouldn’t compare to the potential benefits of the vaccine [13].

**Case presentation**

76 year old woman without a family or personal history of autoimmune disease and the diagnosis of systemic arterial hypertension, grade II obesity (BMI: 39.9) and recent SARS-CoV2 infection (02/06/2021) that didn't require oxygen therapy nor hospitalization. She currently uses nifedipine and metoprolol as her antihypertensive treatment and denies any current use of steroids, statins or recent changes in her medication. She gets the first dose of BNT162b2 mRNA vaccine in March (03/07/2021) and the second dose in April (04/27/2021).

One day after the second dose of the vaccine she presents disseminated dermatosis with erythematous plaques in shoulders, cleavage, abdomen, hips and tights along with bilateral muscle aches 10/10 in VAS in both pelvic and scapular members. 7 weeks later she noticed edema and a violaceous coloration in both eyelids accompanied by weakness with a symmetrical pattern affecting the proximal muscles of the four extremities that limited her daily life activities and later on started with dysphagia to both solids and liquids that made her seek medical assistance in our hospital.

She arrived at the emergency department with the next vitals: Blood pressure: 111/74 mmHg, heart rate: 80 bpm, respiratory rate: 18 breaths per minute, body temperature: 97.16°F, oxygen saturation: 94%. The skin had non-confluent, well defined erythematoviolaceous plaques with hyperpigmentation and scratch marks in the proximal third of arms and tights (Fig. 1). Strength was tested with MMT8 score with 58/75 and there were no changes on osteotendinous reflexes or sensitivity.

Initial laboratory findings evidenced elevation of muscles enzymes, transaminases and lactic dehydrogenase.

The patient got 8.4 points of the EULAR-ACR 2017 criteria [14]: Age of onset ≥ 40 years; Objective symmetric weakness, usually progressive, of the proximal upper extremities; Objective symmetric weakness, usually progressive, of the proximal lower extremities; Neck flexors are relatively weaker than extensors; In lower extremities proximal muscles are relatively weaker than distal ones; Dysphagia or esophageal dysmotility: Elevated serum creatin kinase (CK), dehydrogenase lactate (DHL), aspartate aminotransferase (ASAT/AST/SGOT) or alanine aminotransferase (ALAT/ALT/SGPT). Which classified her as a definite idiopathic inflammatory myopathy with a ≥ 90% diagnostic likelihood, and a 7.5 added score without biopsy and was admitted to fulfill diagnostic protocol and start treatment.

The patient had dysphagia as severity criteria, so after ruling out possible infections we initiated pulses of methylprednisolone for 3 days and after that oral prednisone 1mg/kg/day and intramuscular methotrexate 25mg/week.
During her hospital stay we monitored the muscle enzymes and autoantibodies detection by semi-automatized immunoblot technique (Tables 1 and 2 respectively), and because of her age group and the known association between dermatomyositis and cancer we decided to run cancer screening by doing seric tumor markers and a thoracoabdominal and pelvic tomography that showed no sign of neoplasm.

Electromyography reported changes compatible with active denervation, motor unit potentials with a myopathic pattern and early recruitment with a predominance in proximal muscles in both upper and lower extremities. Motor and sensitive neuroconduction study came out within normal limits (Table 3).

Left deltoid muscle biopsy showed characteristic findings with perivascular and endomysial lymphocytic infiltrate with regenerative and atrophic muscle fibers without necrosis, compatible with dermatomiositis (Fig. 2a–g).

The patient showed adequate clinical response to the high dose of glucocorticoids treatment. Three days after her admission she tolerated oral intake to both solids and liquids and the MMT8 score increased to 52/75 as well as showing shrinking of the dermatosis and no active lesions. She was discharged 7 days after her admission with prednisone and Methotrexate as immunosuppressive agent. A month later in her follow-up visit we found an improvement in his muscle weakness as noted in her MMT8 and CK levels.

**Discussion and conclusion**

The global SARS-CoV2 pandemic has been a challenge to the health authorities and medical science worldwide and it has made us create new protocols to study possible therapies and vaccines.
Is appropriate to remain cautious and vigilant about safety aspects of the COVID-19 vaccines, especially when many of them use new kind of technology (mRNA vaccines) [15]. This fear could be justified by the fact that there has been described more adverse effects in fully vaccinated people who previously had COVID-19.
in comparison to those who are just partially vaccinated (1 dose only) and previously had COVID-19. The antibody production between these two groups is very similar which means these patients could receive only one dose to diminish the incidence of adverse effects associated to vaccination [16].

Finally, we agree that there is an association between myopathies and vaccination (at least a temporal one) and there are few case reports about the SARS-CoV2 vaccine, but these cases are extremely rare and the risk is greatly outweighed by the benefits against this new virus, that’s why vaccination should continue to be encouraged [15].

Abbreviations
COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory disease coronavirus 2; BMI: Body mass index; VAS: Visual analogue scale; mmHg: Millimetre of mercury; bpm: Beats per minute; MMT8: Manual muscle testing 8; EULAR: European league against rheumatism; ACR: American college of rheumatology; CK: Creatin kinase; DHL: Dehydrogenase lactate; ASAT/AST/SGOT: Aspartate aminotransferase; ALAT/ALT/SGPT: Alanine aminotransferase; R: Deltoides; Right deltoids; R: Braqial Biceps; Right Braqial Biceps; Right Com. Dig. Ext.; Right common digital extensor; C. Med. Gastroc: Calf medial gastrocnemius; H&E: Hematoxylin and eosin; IM: Idiopathic inflammatory myopathies;; DM: Dermatomyositis, PM: Polymyositis; NAM: Necrotizing auto-immune myopathy; IBM: Inclusion bodies myopathy; VAERS: Vaccine Adverse Event Reporting System; USA: United States of America; mRNA: Messenger RNA.

Acknowledgements
We would like to acknowledge that all laboratory tests, imaging and the equipment to do complementary studies such as the biopsy and electromyography were provided by the “Instituto Mexicano del Seguro Social (IMSS)”.

Authors’ contributions
HQM contributed to the conceptualization, methodology, writing, editing, and preparation for this original manuscript. MRHZ was responsible of conceptualization, methodology, writing and editing of the report. ACC was responsible of writing and editing of the report. FJJB was responsible for recollecting the data and writing and editing the report. JRHV was responsible of writing and editing of the report. SZZ was responsible of writing and editing of the report. PMR was responsible of recollecting the data and writing and editing the report. FJJB was responsible for recollecting the data and writing and editing the report. SZZ was responsible of writing and editing of the report. JRHV was responsible of writing and editing of the report. ACC was responsible of conceptualization, methodology, writing and editing of the report. PMR was responsible for recollecting the data and writing and editing the report. ACC was responsible for writing and editing of the report. SJH was helped by processing the pathological piece and interpreting the histological findings. SJDAC helped by doing and interpreting the electromyography. All authors have read and approved the manuscript.

Funding
The authors have no funding to declare.

Availability of data and materials
Authors declare the data to support the findings in this study are available in the article.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
All the participants and the patient gave written consent for the use of the clinical details and the identifying pictures of the patient and the histopathological images presented in this article.

Competing interests
The authors declare that they have no conflict of interest.

Received: 28 September 2021 Accepted: 3 February 2022
Published online: 01 April 2022

References
1. Lundberg I, de Visser M, Werth V. Classification of myositis. Nat Rev Rheumatol. 2018;14(5):269–78.
2. Riddell V, Bagby S, McHugh N. Myositis autoantibodies: recent perspectives. Curr Opin Rheumatol. 2020;32(6):548–52.
3. Stübben J. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev. 2014;13(11):31–9.
4. United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990 - 6/25/2021, CDC WONDER On-line Database. Accessed at http://wonder.cdc.gov/vaers.html on Jul 8, 2021 10:57:31 PM
5. Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. Am J Transplant. 2021;21(3):1332–7.
6. Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Rep. 2021;14(6):e243975.
7. Malik B, Kalantary A, Rikabi K, Kunadi A. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. BMJ Case Rep. 2021;14(7):e243894.
8. Bano F, Badugama B, Chandra D. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination: a single UK centre experience. BMJ Case Rep. 2021;14(7):e243931.
9. Suresh P, Petchey W. ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST). BMJ Case Rep. 2021;14(6):e243931.
10. Usvaydah A, Hassan N, Abu Ghoush M, Shahin K. Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination. BMJ Case Rep. 2021;14(4):e242060.
11. Patel S, Khurram R, Lakhami A, Qurk B. Guillain-Bare syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Reports. 2021;14(4):e242956.
12. Mayoclinic.org. 2022. U.S. COVID-19 vaccine tracker. See your state’s progress. https://www.mayoclinic.org/coronavirus-covid-19/vaccine-tracker/. Accessed 27 January 2022
13. Fernando P, Stephen J, Nicholas K, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577
14. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, and Cols. International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec;76(12):1955–1964
15. Gerberding JL, Haynes BF. Vaccine innovations. Past and future. N Engl J Med. 2021;384(5):393–6.
16. Florian K, Komal S, Hala A, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:14.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.